Medicenna Therapeutics Corp. logo

Medicenna Therapeutics Corp.

NASDAQ:MDNA

Overview | Financials
Company Name Medicenna Therapeutics Corp.
Symbol MDNA
Currency USD
Price 0.157
Market Cap 0
Dividend Yield 0%
52-week-range 0.151 - 0.2
Industry Biotechnology
Sector Healthcare
CEO Dr. Fahar Merchant Ph.D.
Website https://www.medicenna.com

An error occurred while fetching data.

About Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well

Related Stocks

Hepion Pharmaceuticals, Inc. logo

Hepion Pharmaceuticals, Inc.

HEPA

0.675 USD

Pro-Dex, Inc. logo

Pro-Dex, Inc.

PDEX

25.5 USD

MEI Pharma, Inc. logo

MEI Pharma, Inc.

MEIP

3.04 USD

Black Diamond Therapeutics, Inc. logo

Black Diamond Therapeutics, Inc.

BDTX

4.73 USD

Molecular Templates, Inc. logo

Molecular Templates, Inc.

MTEM

1.34 USD

Solid Biosciences Inc. logo

Solid Biosciences Inc.

SLDB

7.14 USD

Financials

Numbers are in millions USD

Numbers are in millions USD